Cancer medicines can arrive in the clinic through more than one regulatory pathway, and the number of approvals alone may not reveal how rapidly treatment options are changing. A cross-sectional study published in JAMA examines trends in US Food and Drug Administration approvals for medicines used to treat adult solid tumors from 2006 through 2025. The analysis includes both original approvals, which introduce a new drug or biological product, and supplemental approvals, which expand the use of an already approved medicine to a different cancer, treatment setting, biomarker-defined group, dose, or combination.
The study, led by Bishal Gyawali, MD, PhD, of Queen’s University in Canada, focuses on a period of unusually rapid development in oncology. During these two decades, cancer treatment has been reshaped by targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell-based approaches, and molecularly guided treatment strategies. At the same time, the FDA has increasingly relied on regulatory mechanisms designed to make promising treatments available sooner, including accelerated approval based on surrogate outcomes such as tumor response or progression-free survival.
By examining approvals across a 20-year period, the researchers aim to place individual regulatory decisions within a broader historical pattern. Rather than treating every FDA authorization as an equivalent event, the study distinguishes between first-time approvals and supplemental indications. This distinction is technically important because a supplemental approval may substantially increase the number of patients eligible for an existing therapy without representing the arrival of a new drug. Conversely, a single original approval may later generate many additional indications across tumor types and patient subgroups.
The analysis centers on adult solid tumors, a category that includes cancers arising in organs and tissues such as the lung, breast, colon, prostate, kidney, liver, stomach, pancreas, and ovary. These diseases are biologically diverse, and modern drug development often divides them into increasingly narrow populations defined by genetic alterations, protein expression, immune characteristics, previous treatment, or disease stage. A medicine approved for a molecularly selected group may therefore be relevant to only a fraction of patients with a particular cancer, even when the indication is described broadly in public announcements.
This shift toward precision oncology has changed what an approval represents. In the past, cancer drugs were commonly evaluated according to whether they improved outcomes in a relatively broad disease population. Today, regulatory decisions may depend on a biomarker or molecular alteration that identifies tumors likely to respond to a particular mechanism of action. Such approvals can accelerate access to treatment for patients with rare genomic features, but they also create practical challenges. Testing must be available, results must be interpreted correctly, and clinicians must determine whether evidence from a narrowly defined trial applies to an individual patient.
The FDA’s accelerated approval pathway is another important feature of the period covered by the study. Under this pathway, a drug may receive authorization on the basis of an endpoint considered reasonably likely to predict clinical benefit, while the manufacturer conducts confirmatory studies after approval. In oncology, tumor shrinkage and other intermediate measures have often supported accelerated decisions. These endpoints can provide earlier evidence of activity than overall survival, but they do not always establish that patients live longer or experience a better quality of life. Confirmatory trials are intended to resolve that uncertainty, although delays, inconclusive results, or changes in standard treatment can complicate the process.
Including supplemental indications allows the researchers to capture the expanding regulatory footprint of established cancer medicines. A drug may begin with approval for one advanced cancer and later receive authorization for earlier-stage disease, a different tumor type, a new line of therapy, or use in combination with another agent. Each additional indication may reflect meaningful progress, especially when it is supported by randomized evidence showing improved survival, fewer symptoms, or a longer period before disease progression. However, the clinical importance of supplemental approvals can vary considerably depending on the strength of the evidence and the magnitude of benefit.
The study’s cross-sectional design means that it describes patterns in FDA approvals rather than testing a direct cause-and-effect relationship. It can show how the number and types of approvals changed over time, but it cannot by itself determine whether those changes improved population health, reduced cancer mortality, or increased access to effective care. Approval counts also do not measure affordability, insurance coverage, manufacturing capacity, prescribing patterns, or whether patients ultimately receive the treatments. Those factors can determine the real-world impact of a medicine long after a regulatory decision has been announced.
The findings are expected to inform ongoing debates about how cancer progress should be measured. A growing list of approvals may signal scientific creativity and expanding therapeutic choice, but it may also obscure differences in clinical value. For patients, physicians, policymakers, and researchers, the central question is not only how many treatments reach the market, but how convincingly they improve outcomes that matter. By tracing original and supplemental approvals across adult solid tumors through 2025, the study offers a framework for understanding the changing architecture of cancer medicine and for asking whether regulatory momentum is translating into meaningful benefits for people living with cancer.
Subject of Research: Trends in US FDA approvals of medicines for adult solid tumors from 2006 through 2025, including original and supplemental indications.
Web References: https://doi.org/10.1001/jama.2026.12089
Keywords: Cancer medicine, oncology, solid tumors, FDA approvals, supplemental indications, original approvals, precision oncology, targeted therapy, immunotherapy, accelerated approval, cancer treatment, health care policy
